"Disposant d’une implantation centrale en Alsace du Nord, le Centre Hospitalier de Haguenau (CHH) répond au besoin d’un bassin de population d’environ 300 000 habitants. Son identité est fortement marquée par sa dynamique territoriale, fédérant les acteurs de la santé – publics comme privés, libéraux comme institutionnels, du champ sanitaire comme médico-social – au bénéfice des parcours patients. Depuis 2017, le CHH œuvre en Direction Commune avec le Centre Hospitalier Intercommunal de la Lauter de Wissembourg, et, depuis 2019, avec le Centre Hospitalier Départemental de Bischwiller, constituant ainsi la Coopération Hospitalière Nord Alsace."

During the past decade, Centre Hospitalier de Haguenau conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 2 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 1 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Hospitalier de Haguenau" #1 sponsor was "University Hospital, Strasbourg, France" with 3 trials, followed by "Biotronik France" with 2 trials sponsored, "LivaNova" with 2 trials sponsored, "Terumo Europe N.V." with 2 trials sponsored and "Alvimedica Medical Technologies France" with 2 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Hospitalier de Haguenau" #1 collaborator was "Biotronik SE & Co. KG" with 2 trials as a collaborator, "EVAMED" with 2 trials as a collaborator, "European Cardiovascular Research Center" with 2 trials as a collaborator, "Abbott Medical Devices" with 1 trials as a collaborator and "Allies in Cardiovascular Trials Initiatives and Organized" with 1 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier de Haguenau" are "Coronary Artery Disease" (6 trials), "Acute Myocardial Infarction" (2 trials), "Atrial Fibrillation" (2 trials), "Coronaropathy" (2 trials) and "ACS - Acute Coronary Syndrome" (1 trials). Many other conditions were trialed in "Centre Hospitalier de Haguenau" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier de Haguenau" are "Device" (12 trials), "Drug" (7 trials), "Other" (7 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Assessment by caregivers of the quality of the end of life in intensive care units" (1 trials), "Avelumab" (1 trials), "Blood sampling" (1 trials), "COBRA PzF Coronary Stent System" (1 trials) and "DES-CRE8" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier de Haguenau" are 31 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Centre Hospitalier de Haguenau". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Centre Hospitalier de Haguenau, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier de Haguenau, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 8 trials that are defined as “Not Applicable".